Found 5 clinical trials
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with
- 0 views
- 17 Jan, 2021
- 3 locations
-
Multi-country trial
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Nephrology
-
Currently Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …
- 990 views
- 17 Jan, 2021
- 113 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4
- 63 views
- 23 Jan, 2021
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Gastroenterology
-
Currently Recruiting
Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.
- 0 views
- 25 Jan, 2021
- 1 location
-
Multi-country trial
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Nephrology
-
Currently Recruiting
Ulixertinib in Treating Patients With Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or
- 94 views
- 18 Jan, 2021
- 77 locations